BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

859 related articles for article (PubMed ID: 25536258)

  • 1. Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
    Inzucchi SE; Lipska KJ; Mayo H; Bailey CJ; McGuire DK
    JAMA; 2014 Dec 24-31; 312(24):2668-75. PubMed ID: 25536258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.
    Lazarus B; Wu A; Shin JI; Sang Y; Alexander GC; Secora A; Inker LA; Coresh J; Chang AR; Grams ME
    JAMA Intern Med; 2018 Jul; 178(7):903-910. PubMed ID: 29868840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin: time to review its role and safety in chronic kidney disease.
    Tanner C; Wang G; Liu N; Andrikopoulos S; Zajac JD; Ekinci EI
    Med J Aust; 2019 Jul; 211(1):37-42. PubMed ID: 31187887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
    Salpeter S; Greyber E; Pasternak G; Salpeter E
    Cochrane Database Syst Rev; 2003; (2):CD002967. PubMed ID: 12804446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
    Salpeter S; Greyber E; Pasternak G; Salpeter E
    Cochrane Database Syst Rev; 2002; (2):CD002967. PubMed ID: 12076461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
    Salpeter S; Greyber E; Pasternak G; Salpeter E
    Cochrane Database Syst Rev; 2006 Jan; (1):CD002967. PubMed ID: 16437448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? No, We Should Never Again Compromise Safety!
    Kalantar-Zadeh K; Kovesdy CP
    Diabetes Care; 2016 Jul; 39(7):1281-6. PubMed ID: 27330129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin in chronic kidney disease: time for a rethink.
    Heaf J
    Perit Dial Int; 2014 Jun; 34(4):353-7. PubMed ID: 24711640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease.
    Sipahi S; Solak Y; Acikgoz SB; Genc AB; Yildirim M; Yilmaz U; Nalbant A; Tamer A
    Int Urol Nephrol; 2016 Aug; 48(8):1305-1312. PubMed ID: 27102431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?
    Bakris GL; Molitch ME
    Diabetes Care; 2016 Jul; 39(7):1287-91. PubMed ID: 27330130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unleash metformin: reconsideration of the contraindication in patients with renal impairment.
    Lu WR; Defilippi J; Braun A
    Ann Pharmacother; 2013 Nov; 47(11):1488-97. PubMed ID: 24259604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
    Chu PY; Hackstadt AJ; Chipman J; Griffin MR; Hung AM; Greevy RA; Grijalva CG; Elasy T; Roumie CL
    Diabetes Care; 2020 Jul; 43(7):1462-1470. PubMed ID: 32327421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data.
    Rhee CM; Kovesdy CP; Kalantar-Zadeh K
    Nephron; 2017; 135(2):147-153. PubMed ID: 27760420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
    Salpeter SR; Greyber E; Pasternak GA; Salpeter EE
    Cochrane Database Syst Rev; 2010 Apr; 2010(4):CD002967. PubMed ID: 20393934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactic acidosis associated with metformin in patients with moderate to severe chronic kidney disease: study protocol for a multicenter population-based case-control study using health databases.
    Pedrós C; Ávila M; Gómez-Lumbreras A; Manríquez M; Morros R;
    BMC Nephrol; 2019 May; 20(1):193. PubMed ID: 31146690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proposal for the modification of metformin use in patients with chronic kidney disease].
    Balogh Z; Mátyus J
    Orv Hetil; 2012 Sep; 153(39):1527-35. PubMed ID: 23000419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin in patients with chronic kidney disease: strengths and weaknesses.
    Rocha A; Almeida M; Santos J; Carvalho A
    J Nephrol; 2013; 26(1):55-60. PubMed ID: 22641582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
    Salpeter SR; Greyber E; Pasternak GA; Salpeter Posthumous EE
    Cochrane Database Syst Rev; 2010 Jan; (1):CD002967. PubMed ID: 20091535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association between Metformin Therapy and Lactic Acidosis.
    Kuan IHS; Savage RL; Duffull SB; Walker RJ; Wright DFB
    Drug Saf; 2019 Dec; 42(12):1449-1469. PubMed ID: 31372935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactic acidosis induced by metformin: incidence, management and prevention.
    Lalau JD
    Drug Saf; 2010 Sep; 33(9):727-40. PubMed ID: 20701406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.